FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 725 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Cancer in My Community: Accessing Care Through the Public Health System... May 9, 2023 EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine September 30, 2024 Preparing for your COVID-19 Vaccine: What to Ask your Provider February 1, 2021 NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in... May 8, 2024 Load more HOT NEWS Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... Adding Retifanlimab To Chemotherapy Provides OS Benefit over Chemotherapy In First-Line... ¿Qué es la escasez de medicamentos y cómo puede afectar a... EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride
